Concepedia

Publication | Open Access

Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease

DOIFull Paper Access

242

Citations

40

References

2021

Year

Stefan Schreiber, Konrad Aden, Joana P. Bernardes, Claudio Conrad, Florian Tran, Hanna Höper, Valery Volk, Neha Mishra, Johanna I. Blase, Susanna Nikolaus,
Gastroenterology

Abstract

Our data suggest that blockade of IL6 trans-signaling holds great promise for the therapy of IBD and should undergo full clinical development as a new immunoregulatory therapy for IBD. (EudraCT no., Nu 2016-000205-36).

References

YearCitations

Page 1